Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block ofN-type calcium channelsantagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research^[1].

Most native cells express a variety of different calcium channels and as a result, Ziconotide TFA only partially reduces high-voltage-activated calcium currents in differentiated human neuroblastoma IMR32 cells, rat superior cervical ganglion neurons, and rat hippocampal neurons. Ziconotide TFA also reduces calcium currents that result from expression of the α1B subunit in HEK cells, tsa-201 cells, and Xenopus laevis oocytes^[1].
Ziconotide TFA delivers its antinociceptive efficacy by reducing the release of pronociceptive neurotransmitters in the dorsal horn of the spinal cord, thereby inhibiting pain signal transmission^[1].

Ziconotide (i.t.; 25-100 pmol/site; 5 μL; on the 4 th, 10 th, 15 th, 20 th, and 24 th days) TFA reduces the levels of IL-1β and IL-23 in the CNS, as well as IL-17 production in the spleen, 25 days after MOG35-55-elicited EAE, in the mouse model of experimental autoimmune encephalomyelitis (EAE)^[2].

3437.30

C₁₁₆H₁₇₉F₂₁N₃₆O₄₆S₇

CKGKGAKCSRLMYDCCTGSCRSGKC-NH2(Disulfide bridge:Cys1-Cys16;Cys8-Cys20;Cys15-Cys25)

齐考诺肽TFA

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.